Therapie von Urtikaria und atopischer Dermatitis bei einer Patientin mit Dupilumab

Föhr, Julia; Herbst, Matthias; Jahn, S.

doi:10.1007/s00105-020-04675-3

Cited by 10 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biologics targeting type 2 inflammatory mediators for the treatment of CU have also been reported. Dupilumab, an iconic biological agent for type 2 inflammation that targets the IL-4 and IL-13 signaling pathways ( 138 ), has been suggested to successfully treat patients with refractory CU who are refractory to omalizumab in case reports and case series ( 139 – 141 ). Two phase 3 trials (LIBERTY-CUPID Studies A and B, NCT03749135) that evaluate the efficacy of dupilumab for the treatment of CSU that was uncontrolled by standard-of-care antihistamines (CUPID Study A) and or by standard-of-care antihistamines and omalizumab (CUPID Study B) have been completed.…”

Section: Biologics In Atopic Diseases and Cumentioning

confidence: 99%

Atopy in chronic urticaria: an important yet overlooked issue

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Chronic urticaria (CU) is one of the most common dermatological diseases and has a significant impact on the quality of life of patients. However, the pathogenesis of this disease remains unclear. Autoimmunity in chronic spontaneous urticaria (CSU) has received considerable attention and has been studied previously. Atopy is an important characteristic of CU; however, it has not been fully recognized. Atopy predisposes individuals to immune responses to allergens, leading to type 2 inflammation and immunoglobulin E (IgE) overproduction. Compared with healthy individuals, patients with CU have a higher proportion of atopy, and an atopic background is correlated with the clinical characteristics of CU. The total IgE levels in patients with CU is significantly higher than those in healthy individuals. Although its level is not higher than that in classic allergic diseases, it is closely related to CU. Exogenous allergens, auto-allergens, and specific IgEs, which are closely related to atopy, have been reported, and their roles in CU pathogenesis are also being studied. Local and systemic atopic inflammation is present in patients with CU. This review summarizes the current knowledge regarding atopy and CU, speculating that there are CU subtypes, such as atopic CSU or atopic chronic inducible urticaria (CIndU) and that atopy may be involved in the pathogenesis of CU. These findings provide a new perspective for a comprehensive understanding of the clinical features of CU and further research regarding its pathogenesis.

show abstract

Section: Biologics In Atopic Diseases and Cumentioning

confidence: 99%

Atopy in chronic urticaria: an important yet overlooked issue

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Drei Monate nach Abschluss der Omalizumab-Therapie kam es zum Rezidiv der CSU. Wir erreichten deren Besserung und eine anhaltende Remission der atopischen Dermatitis mit einer Dupilumab-Therapie, die wir 4 Monate nach Abschluss der Behandlung mit Omalizumab begannen [ 8 ]. Wir beobachteten einen stabilen, kontrollierten klinischen Zustand der atopischen Dermatitis und der Urtikaria über 14 Monate.…”

Section: Besondere Kasuistikenunclassified

Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis

Diamanti¹,

Föhr²,

Papageorgiou³

et al. 2022

Dermatologie

Self Cite

View full text Add to dashboard Cite

“…A systematic literature search identified a single case report in Germany on the treatment of simultaneous CSU and AD with dupilumab monotherapy, which reported complete remission of both diseases in a 21‐year‐old female 1 . Adding dupilumab to omalizumab in patients with coexisting CSU and AD appears to be a safe and effective treatment option, although data from more patients on long‐term treatment are warranted.…”

Section: Figurementioning

confidence: 99%